Recent

% | $
Quotes you view appear here for quick access.

OCATA THERAPEUTICS, INC. Message Board

tazamatic2002 15 posts  |  Last Activity: Jul 1, 2015 11:25 PM Member since: Jun 1, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tazamatic2002 by tazamatic2002 Jul 1, 2015 11:25 PM Flag

    Enrollment:

    56

    Study Start Date:
    November 2012

    Estimated Study Completion Date:
    January 2019

    Estimated Primary Completion Date:
    March 2017 (Final data collection date for primary outcome measure)

    Arms
    Assigned Interventions

    Experimental: Arm A
    Myelofibrosis (MF) participants will receive Imetelstat, 9.4 milligram per kilogram (mg/kg), intravenously [IV] as 2 hour infusion, on Day 1 of every 21-day cycle up to 3 years until disease progression or unacceptable toxicity.

    Drug: Imetelstat
    Imetelstat Sodium administered as IV over 2 hours with treatment up to 3 years until disease progression or unacceptable toxicity with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.

    Other Name: GRN163L


    Experimental: Arm B
    MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15 of Cycle 1, then Day 1 of each subsequent 21-day cycle up to 3 years until disease progression or unacceptable toxicity.

    Drug: Imetelstat
    Imetelstat Sodium administered as IV over 2 hours with treatment up to 3 years until disease progression or unacceptable toxicity with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.

    Other Name: GRN163L


    Experimental: Arm D
    Blast phase MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15, 22 of every 28-day cycle up to 3 years until disease progression or unacceptable toxicity.

    Drug: Imetelstat
    Imetelstat Sodium administered as IV over 2 hours with treatment up to 3 years until disease progression or unacceptable toxicity with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.

    Other Name: GRN163L

  • Reply to

    Back in short

    by larrythelumberjack Jun 29, 2015 1:56 PM
    tazamatic2002 tazamatic2002 Jul 1, 2015 11:18 PM Flag

    so much for having shorted at $4.60 when it was no where near that when you posted this

  • The number of trial sites is now 32

  • Looks like INCY will e a shortt in 2 years

  • The unsatisfactory outcomes for osteosarcoma necessitate novel therapeutic strategies. This study evaluated the effect of the telomerase inhibitor imetelstat in pre-clinical models of human osteosarcoma. Because the chaperone molecule HSP90 facilitates the assembly of telomerase protein, the ability of the HSP90 inhibitor alvespimycin to potentiate the effect of the telomerase inhibitor was assessed. The effect of single or combined treatment with imetelstat and alvespimycin on long-term growth was assessed in osteosarcoma cell lines (143B, HOS and MG-63) and xenografts derived from 143B cells. Results indicated that imetelstat as a single agent inhibited telomerase activity, induced telomere shortening, and inhibited growth in all three osteosarcoma cell lines, though the bulk cell cultures did not undergo growth arrest. Combined treatment with imetelstat and alvespimycin resulted in diminished telomerase activity and shorter telomeres compared to either agent alone as well as higher levels of γH2AX and cleaved caspase-3, indicative of increased DNA damage and apoptosis. With dual telomerase and HSP90 inhibition, complete growth arrest of bulk cell cultures was achieved. In xenograft models, all three treatment groups significantly inhibited tumor growth compared with the placebo-treated control group, with the greatest effect seen in the combined treatment group (imetelstat, p= 0.045, alvespimycin, p=0.034; combined treatment, p=0.004). In conclusion, HSP90 inhibition enhanced the effect of telomerase inhibition in pre-clinical models of osteosarcoma. Dual targeting of telomerase and HSP90 warrants further investigation as a therapeutic strategy.

  • tazamatic2002 tazamatic2002 May 12, 2015 10:39 PM Flag

    Are you Michael Torres?

  • Reply to

    10 Things Believers Believe

    by irishtrader52 Mar 8, 2015 12:29 PM
    tazamatic2002 tazamatic2002 May 11, 2015 4:21 PM Flag

    Irish I will be at the shareholder meeting this year is there anything you wouldlike me to ask (Chip) Dr John Scarlett before the meeting or during the meeting.

  • tazamatic2002 tazamatic2002 Apr 24, 2015 7:52 PM Flag

    The normal process is to list the trial without the sites then either add the sites in blocks or when the sites come on line. Janssen is running the show they know what they are doing. Just because it is your first rodeo you do not need to spread undue fear about trial sites. Running around tilting at windmills does no one any good.

  • tazamatic2002 by tazamatic2002 Apr 21, 2015 2:02 PM Flag

    AST jumps 12% on the trial Balloon VAC1 the market forgets that VAC1 will not go to phase 3 because it costs to much per patient to make it viable. Okarma made it clear when he said 4 months of cleanroom time per patient puts the cost of VAC1 out of reach. VAC1 was to prove the concept for VAC2 the of the shelf multi Cancer targeting Dendridic Cancer Vaccine. VAC2 has been shipped out to the UK for a Phase 1 trial and AST retains rites to reaquire VAC2 post phase 1.

  • Reply to

    What If...

    by irishtrader52 Apr 19, 2015 5:45 PM
    tazamatic2002 tazamatic2002 Apr 20, 2015 10:54 AM Flag

    beaver you know about the typo but you do not know about the patent for the oral version that the patent 8,906,615 allows to be made. Oligonucleatides that are constructed in a way that allows them to be ingested.

  • Reply to

    irish

    by ligas3 Apr 17, 2015 8:32 AM
    tazamatic2002 tazamatic2002 Apr 17, 2015 4:33 PM Flag

    Intermediate and high risk MF has a high mortality rate and short life expectancy. What Phil from seeking Alpha had said was only 2 died while on Imetelstat and one of those was atributed to Imetelstat dosing and lead to changes that labs now point to when dosing should be held.

  • Reply to

    resistant to treatment ?

    by junkbuzzard Apr 16, 2015 6:00 PM
    tazamatic2002 tazamatic2002 Apr 17, 2015 3:53 PM Flag

    The hypothesis is that solid tumors contain a mixture of mutated cells most cells use the telomerase pathway while some use the ALT pathway. When one targets Telomerase without targeting ALT then those ALT cells multiply and fill the void. The other hypothesis is that long term exposure to telomerase inhibitors give rise to ALT mutant strains of Cancer. When Imetelstat is combined with the PARP inhibitor 3AB it works faster and no ALT mutations develop. The other combination is Imetelstat with CDKN1A targeted therapies from the Yale/UCDavis study. That showed un believable results in solid tumor cell lines.

  • Reply to

    AST profits

    by goodchanceofsuccesshere Apr 16, 2015 5:04 PM
    tazamatic2002 tazamatic2002 Apr 16, 2015 5:23 PM Flag

    5% if they take it to market themselves but if they liscense it out or sell it 50%.

  • The transfer is complete

  • tazamatic2002 by tazamatic2002 Apr 6, 2015 3:12 PM Flag

    Annual shareholders meeting at the Westin San Fransisco Airport

ACTC
0.00(0.00%)